Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1)
NEW YORK--(BUSINESS WIRE)--Ophthotech announced that the first patient has been enrolled in the Phase 2b clinical trial assessing Zimura® in patients with Stargardt disease.